The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | High CSF1R expression is associated with immune suppression and poor outcomes in gastric cancer
Kyosuke Seguchi, MD, Kameda Medical Center, Kamogawa, Japan, presents background and findings from MONSTAR-SCREEN-2, a prospective molecular profiling study examining CSF1R expression in gastric cancer. Gene Set Enrichment Analysis found high CSF1R expression was associated with shorter overall survival (OS), whilst multivariable analysis found high CSF1R expression trended towards worse OS. CSF1R-high tumors were found to be enriched with macrophage-related genes, inflammatory pathways, inhibitory checkpoint molecules, T-cell exhaustion signatures and immunoregulatory genes, indicating an immunosuppressive tumor microenvironment. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
